Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

Phase 2Active Not RecruitingNCT05925530

AstraZeneca142 enrolled

Overview

The purpose of this study is to assess efficacy and safety of neoadjuvant durvalumab in combination with platinum-based chemotherapy (CT) given as initial therapy after cancer diagnosis followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab given alone as further therapy in participants with resectable and borderline resectable stage IIB-IIIB NSCLC.

This will be a multicentre, Phase II, single-arm, global study assessing the efficacy and safety of neoadjuvant durvalumab and platinum-based CT, given intravenously, followed by either surgery and adjuvant durvalumab or definitive CRT and consolidation durvalumab in participants with resectable and borderline resectable stage IIB-IIIB NSCLC. Neoadjuvant Period A: All participants will initially receive 2 cycles of neoadjuvant durvalumab + CT (investigator's choice platinum-based) every three weeks. Participants will be assessed for resectability by a multidisciplinary team. Neoadjuvant Period B: Cohort 1: Participants who are deemed eligible for surgery will receive study intervention every three weeks for an additional one and up to two cycles, followed by surgery. CRT: Cohort 2: Participants with unresectable tumours (according to MDT re-assessment) will receive definitive CRT (6 one-week cycles) for approximately six weeks. Both cohorts will then go on to receive durvalumab every four weeks until disease progression or recurrence or up to one year.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

142

Conditions

Non-small Cell Lung Cancer

Interventions

DurvalumabDRUG

Participants that go on to receive surgery, will receive durvalumab for up to four cycles prior to surgery. Participants that go on to receive CRT will receive durvalumab for up to two cycles prior to CRT. All participants will receive durvalumab every four weeks until disease progression or recurrence or up to 12 months following surgery/CRT, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 130 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Deemed resectable or borderline resectable at baseline, confirmed by MDT evaluation at diagnosis. * Previously untreated and pathologically confirmed Stage IIB to select \[i.e.N2\] Stage IIIB by AJCC v8. * Nodal status confirmed with whole body FDG-PET and biopsy via endobronchial ultrasound, mediastinoscopy, or thoracoscopy. * Mandatory brain MRI. * EGFR and ALK wild-type. * Medically operable: adequate cardiac and lung function to undergo resection. * Participant must be ≥ 18 years, at the time of screening. * Histologically or cytologically documented NSCLC. * Minimum life expectancy of 12 weeks. * Minimum body weight of 30 kg. * Male and female participants must be willing to use acceptable methods of contraception. * Female participants of childbearing potential must have negative pregnancy test. Exclusion Criteria: * Unresectable NSCLC confirmed by MDT evaluation at baseline * Stage IIIC patients * Participants whose planned surgery at enrollment is a wedge resection * Known EGFR mutation or ALK translocation * Participants contraindicated for surgical intervention due to comorbid conditions * Participants who are allergic to study intervention. * Participants with more than one primary tumour. * Known active hepatitis infection, positive HCV antibody, HBsAg or HBV core antibody (anti-HBc), at screening. * Female participants who are pregnant or breastfeeding. * Judgement by the investigator that the participant should not participate in the study. * Previously infected or tested positive for human immunodeficiency virus.

Locations (49)

Research Site

The Bronx, New York, United States

Research Site

Houston, Texas, United States

Research Site

Charlottesville, Virginia, United States

Research Site

Vienna, Austria

Research Site

Vienna, Austria

Research Site

Kingston, Ontario, Canada

Outcomes

Primary Outcomes

Resection rate

Resection rate is defined as the proportion of all participants who underwent definitive surgery. Participants who undergo (ie, start) surgery with the goal of complete tumour resection will be counted as meeting this endpoint.

Time frame: At day of surgery (Within 40 days of the last dose of neoadjuvant treatment)

Secondary Outcomes

Resection rate

Resection rate will be further assessed separately in participants deemed resectable at baseline and participants deemed borderline resectable at baseline.

Time frame: At the day of surgery (within 40 days after the last dose of neoadjuvant treatment)

R0, R1, R2 resection rates

The R0, R1, and R2 resection rates (assessed separately) are defined as the proportion of resected participants with resection margins assessed as R0, R1, and R2 respectively. R0 corresponds to resection for cure or complete remission, R1 to microscopic residual tumour, R2 to macroscopic residual tumour.

Time frame: At the day of surgery (within 40 days after the last dose of neoadjuvant treatment)

Pathological complete response (pCR)

pCR will be defined as the proportion of participants who undergo surgery and have 0% residual viable tumour cells in resected lung and lymph nodes.

Time frame: At the day of surgery (within 40 days after the last dose of neoadjuvant treatment)

Overall Survival (OS)

OS will be defined as the time from first dose of study intervention until the date of death due to any cause.

Time frame: From first dose of study intervention until death, withdrawal of consent, or the end of the study (approximately 3.5 years)

Overall Survival (OS) rate

The proportion of participants alive at 12 and 24 months.

Time frame: At 12 months and 24 months

Event-free survival (EFS)

EFS is defined as the time from the first dose of study intervention to any of the following events: PD that precludes surgery, progression or recurrence of disease after surgery, PD in the absence of surgery, disease progression, recurrence, or death due to any cause.

Time frame: From first dose of study intervention until progression of disease (PD), recurrence or death, withdrawal of consent, or the end of the study (approximately 3.5 years)

Event-free survival (EFS) rate

The proportion of participants alive and event-free at 12 and 24 months.

Time frame: At 12 months and 24 months

Progression Free Survival (PFS)

PFS is defined as the time from the first dose of study intervention to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.-defined PD, as assessed by the investigator, or death due to any cause.

Time frame: From first dose of study intervention until disease progression, death, withdrawal of consent, or the end of the study (approximately 3.5 years)

Progression Free Survival (PFS) rate

The proportion of participants alive without disease progression at 12 and 24 months.

Time frame: At 12 months and 24 months

Objective response rate (ORR) pre-surgery/pre-chemoradiotherapy (CRT)

ORR is defined as the proportion of participants who have unconfirmed complete response or partial response as assessed by the investigator per RECIST 1.1.

Time frame: From first dose of study intervention until death, surgery/start of CRT

ORR during study intervention and definitive CRT

ORR is defined as the proportion of participants who have unconfirmed complete response or partial response as assessed by the investigator per RECIST 1.1.

Time frame: From MDT re-assessment timepoint (baseline for this endpoint) until the first tumour assessment after definitive CRT

Percentage of all participants with circulating tumor DNA (ctDNA) clearance

Circulating tumour DNA clearance (ie, cMR) will be defined as a change from detectable ctDNA to undetectable ctDNA (ctDNA concentration less than limit of detection) at specified timepoints. The percentage of all biomarker-evaluable participants with ctDNA clearance will be assessed.

Time frame: From Cycle 1 Day 1 up to pre-surgery/CRT (within 7 to 14 days pre-surgery/CRT) [Each cycle is of 3 weeks]

Number of participants with adverse events

Safety and tolerability will be evaluated in terms of adverse events and serious adverse events.

Time frame: From enrollment up to at least 90 days after last dose of study intervention

Surgical safety: Duration of surgical procedure

The safety of study intervention will be evaluated from start to end of surgery

Time frame: Time from start of surgery to end of surgery

Surgical safety: Length of post operative hospital stay

The safety of study intervention will be evaluated during post operative hospital stay

Time frame: Time from the beginning of the surgery/procedure to the discharge of hospital

Surgical safety: Intended surgical approach

Intended surgical approach at baseline (minimally invasive vs open thoracotomy).

Time frame: At baseline

Surgical safety: Actual surgical approach

Actual surgical approach (minimally invasive vs open thoracotomy).

Time frame: At surgery

Surgical safety: Intended surgical procedure

Intended surgical procedure (lobectomy vs bilobectomy vs sleeve resection vs pneumonectomy).

Time frame: At baseline

Surgical safety: Actual surgical procedure

Actual surgical procedure (lobectomy vs bilobectomy vs sleeve resection vs pneumonectomy)

Time frame: At surgery

Number of participants with delayed surgery

The safety of study intervention will be evaluated for participants with delayed surgery

Time frame: 40 days after last dose of study intervention to surgery

Surgical safety: Length of surgical delays

The safety of study intervention will be evaluated during the length of the surgical delay

Time frame: 40 days after last dose of study intervention to surgery

Number of participants with reason of surgical delay

The safety of study intervention will be evaluated for participants with reason of surgical delay

Time frame: 40 days after last dose of study intervention to surgery

Time from last neoadjuvant dose to surgery

The safety of the study intervention will be evaluated from last neoadjuvant dose to surgery

Time frame: Time from last neoadjuvant dose of study intervention to surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Research Site

Chicoutimi, Quebec, Canada

Research Site

Montreal, Quebec, Canada

Research Site

Brno, Czechia

Research Site

Olomouc, Czechia

...and 39 more locations